Navigation Links
Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Date:3/13/2008

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue will present a corporate overview on Thursday, March 20, 2008 at 11:00am Eastern Time (8:00am Pacific Time) during the Cowen and Company 28th Annual Health Care Conference at the Marriott Copley Place in Boston, Massachusetts.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentation, click on the Investor Relations tab and then click on the link entitled "Events and Presentations" on the left side of the screen. A replay of the webcast will available approximately one hour after the live webcast concludes and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

(858) 436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
9. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. NPS Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):